Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.
|Slideshows|December 12, 2019
7 anxiety disorders: Stimuli and fears
Author(s)Mary Beth Nierengarten, MA
Because appropriate early treatment of anxiety disorders is key to either preventing or reducing a negative impact on a child's life, it's important for the clinician to diagnose the correct disorder by identifying the "threat" and feared stimuli. Here's a look at 7 types of anxiety disorders and their common behaviors.
Advertisement
Advertisement
Related to this article
Learn when your baby is ready for solids, choose safe purees or finger foods, prevent choking, prioritize iron, and introduce allergens confidently.
Christina Boull, MD, shares recommendations for infant skin care, including choosing gentle cleansers, avoiding irritants, and supporting the skin barrier.
Completing the DTaP primary series was 96.2% effective against pertussis in Alaska children aged 6 months to 6 years during a record 2024 outbreak.
Keisha L. Gibson, MD, MPH, discusses the FDA approval of Gazyva for childhood-onset INS and its implications for relapse prevention and pediatric care.
Hai D. Nguyen-Tran, MD, discusses clinical signs, neurologic warning symptoms, supportive care, and preventing the spread of hand, foot, and mouth disease.
Topical botanical Cinainu earned FDA Breakthrough Therapy status for AA in patients aged 2+, supported by phase 2/3 RAAINBOW data in children.
The FDA accepted the Anaphylm NDA resubmission as a class 2 response, setting a March 16, 2027, PDUFA date for the sublingual epinephrine film.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
Hand, foot, and mouth disease: Red flags pediatricians should know
2
Early choline in FASD tied to IQ, memory gains 5 years later
3
FDA sets new PDUFA date for Anaphylm for type I allergic reactions
4
Starting solids: When to begin, what to offer, and how much
5